|Bid||87.36 x 800|
|Ask||260.00 x 800|
|Day's range||213.82 - 219.32|
|52-week range||203.37 - 460.21|
|Beta (5Y monthly)||1.27|
|PE ratio (TTM)||26.05|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Charles River's (CRL) industry knowledge in plasmid DNA production will benefit Ziphius Vaccines' early-stage saRNA manufacturing program.
It is hard to get excited after looking at Charles River Laboratories International's (NYSE:CRL) recent performance...
Charles River (CRL) broadens the scope of the products and services across the drug discovery and early-stage development continuum through focused acquisitions.